Ziprasidone hydrochloride_product_DataBase

Bioactivity	Ziprasidone (CP-88059) hydrochloride is an orally active combined 5-HT and dopamine receptor antagonist[1]. Ziprasidone hydrochloride has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM)[1].
Invitro	Ziprasidone hydrochloride (0-500 nM, 150 seconds) blocks wild-type hERG current[2]. Cell Viability Assay[2] Cell Line:
In Vivo	Ziprasidone hydrochloride (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold[3]. Animal Model:
Name	Ziprasidone hydrochloride
CAS	122883-93-6
Formula	C21H22Cl2N4OS
Molar Mass	449.40
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Rollema H, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48(3):229-237. [2]. Schmidt AW, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425(3):197-201. [3]. Seeger TF, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995;275(1):101-113. [4]. Park S, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012;61(6):787-793.

PeptideDB